Market Overview

EU5 Conjugate Vaccine Market Analysis & Forecasts 2018-2023 - ResearchAndMarkets.com

Share:

The "EU5
Conjugate Vaccine Market (2018-2023)"
report has been added to ResearchAndMarkets.com's
offering.

Conjugate Vaccine is a type of vaccine that contains bacterial capsular
polysaccharide, attached to a protein to enhance immunogenicity and
protect against invasive diseases. EU5 is one of the most prominent
markets for conjugate vaccines.

The U.K. was the first country to introduce MenB-4C into their National
Infant Immunization Program (2015). In all EU/EEA countries, Hib
vaccination has been part of the immunization programs, since 2010, and
high coverage has been sustained.

Key growth factors:

The EU5 is projected to have positive growth during the forecasted
period. A higher number of vaccination programs by the governments,
increase in geriatric population, government initiatives and increase in
research and development activities together propel the growth of this
market. Germany will grow at a considerable rate over the coming years
owing to increasing government initiatives which offer medical advice
for the vaccination of children. Rising prevalence of infectious
diseases and focused product development will fuel industry expansion.

What's covered in the report?

1. Overview of the EU5 conjugate vaccine market

2. Market drivers and challenges in the EU5 conjugate vaccine market

3. Market trends in the EU5 conjugate vaccine market

4. Historical, current and forecasted market size data for EU5 based on
disease indication (pneumococcal, haemophilus influenza type b,
diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) - by
revenue and by volume

5. Historical, current and forecasted market size data for EU5 based on
end user (pediatric and adult conjugate vaccines) - by revenue and by
volume

6. Analysis of the competitive landscape and profiles of major companies
operating in the EU5 market

Companies Mentioned

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited

Key Topics Covered:

Chapter 1: Executive summary

Chapter 2: Market overview

Chapter 3: EU5 major segment overview - by disease indication

Chapter 4: EU5 major segment overview - by end user

Chapter 5: Competitive landscape

For more information about this report visit https://www.researchandmarkets.com/research/3gfjnt/eu5_conjugate?w=4

View Comments and Join the Discussion!